


PRODUCT INFORMATION



NU 6102

Item No. 13317

CAS Registry No.: 444722-95-6
Formal Name: 4-[[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino]-benzenesulfonamide
MF: C₁₈H₂₂N₆O₃S
FW: 402.5
Purity: ≥90%
UV/Vis.: λ_{max}: 309 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

NU 6102 is supplied as a crystalline solid. A stock solution may be made by dissolving the NU 6102 in the solvent of choice, which should be purged with an inert gas. NU 6102 is soluble in organic solvents such as ethanol and DMSO. The solubility of NU 6102 in these solvents is approximately 1 mg/ml.

Description

Cyclin-dependent kinases (CDKs) play a key role in regulating cell division by phosphorylating distinct substrates in different phases of the cell cycle. Cell cycle deregulation in many cancers often results from altered CDK activity. Thus, CDKs are potential pharmacological targets for anticancer agents. NU 6102 is a potent inhibitor of Cdk1 and Cdk2 with K_i values of 9 and 6 nM and IC₅₀ values of 9.5 and 5.4 nM, respectively.^{1,2} NU 6102 inhibits Cdk4 activity with an IC₅₀ value of 1.6 μM, suggesting it is most selective for Cdk2.³ Time-lapse videomicroscopy reveals that 20 μM NU 6102 delays cell entry into mitosis where most cells appear to eventually complete mitotic division but cannot correctly undergo cytokinesis, and hence become binucleated with an abnormal number of centrosomes.⁴ In SKUT-1B cancer cells a 24 h exposure to NU 6102 induced G₂ arrest, inhibition of target protein phosphorylation, and cytotoxicity with an LC₅₀ value of 2.6 μM.⁴

References

1. Sayle, K.L., Bentley, J., Boyle, F.T., *et al.* Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. *Bioorg. Med. Chem. Lett.* **13(18)**, 3079-3082 (2003).
2. Hardcastle, I.R., Arris, C.E., Bentley, J., *et al.* N²-substituted O⁶-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 2. *J. Med. Chem.* **47(15)**, 3710-3722 (2004).
3. Pratt, D.J., Bentley, J., Jewsbury, P., *et al.* Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. *J. Med. Chem.* **49(18)**, 5470-5477 (2006).
4. Krasinska, L., Cot, E., and Fisher, D. Selective chemical inhibition as a tool to study Cdk1 and Cdk2 functions in the cell cycle. *Cell Cycle* **7(12)**, 1702-1708 (2008).
5. Thomas, H.D., Wang, L.-Z., Roche, C., *et al.* Preclinical *in vitro* and *in vivo* evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU 6102 and a water soluble prodrug NU6301. *Eur. J. Cancer* **47(13)**, 2052-2059 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/16/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM